314 studies found for:    "Alkylating Agents" | updated in the last 30 days
Show Display Options
Rank Status Study
1 Recruiting Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer
Condition: Extensive-stage Small Cell Lung Cancer
Interventions: Drug: Temozolomide;   Drug: first-line chemotherapy;   Radiation: Prophylactic cranial irradiation;   Radiation: thoracic radiotherapy
2 Recruiting Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma
Condition: Pineoblastoma
Interventions: Drug: Temozolomide;   Drug: Irinotecan;   Drug: Dasatinib;   Drug: Rapamycin
3 Not yet recruiting Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Radiation: Thoracic RT;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Nivolumab;   Other: Placebo
4 Not yet recruiting Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: Drug: Nivolumab;   Drug: Cisplatin;   Drug: Cetuximab;   Radiation: IMRT
5 Not yet recruiting Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Selinexor;   Drug: Melphalan;   Drug: Dexamethasone;   Procedure: Autologous Hematopoietic Cell Transplantation (HCT)
6 Recruiting Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM
Condition: Glioblastoma Multiforme
Intervention: Drug: Metformin
7 Recruiting HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen
Condition: Sickle Cell Disease
Intervention: Drug: Fludarabine monophosphate
8 Not yet recruiting Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
Conditions: Adult Solid Neoplasm;   Childhood Solid Neoplasm;   Metastatic Neoplasm
Interventions: Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL;   Biological: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine;   Procedure: Positron Emission Tomography
9 Not yet recruiting Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1
Conditions: HLA-A2 Positive Cells Present;   Metastatic Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain
Interventions: Biological: Aldesleukin;   Biological: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis
10 Recruiting Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Drug: Prednisone
11 Not yet recruiting A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients
Condition: Diffuse Large B Cell Lymphoma
Interventions: Drug: SCT400 plus CHOP;   Drug: Rituximab plus CHOP
12 Recruiting Response-based Treatment of High-risk Neuroblastoma
Condition: Newly Diagnosed High Risk Neuroblastoma
Interventions: Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Carboplatin;   Procedure: Tandem HDCT/auto-SCT;   Radiation: Radiotherapy;   Drug: Interleukin-2;   Drug: Isotretinoin;   Radiation: MIBG
13 Not yet recruiting A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
Condition: Glioblastoma
Interventions: Drug: Temozolomide;   Drug: Aprepitant;   Drug: Minocycline;   Drug: Disulfiram;   Drug: Celecoxib;   Drug: Sertraline;   Drug: Captopril;   Drug: Itraconazole;   Drug: Ritonavir;   Drug: Auranofin
14 Not yet recruiting Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Pembrolizumab;   Drug: Cyclophosphamide
15 Recruiting Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
16 Not yet recruiting Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
Condition: Sickle Cell Disease
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: r-ATG;   Procedure: Bone Marrow Transplant;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Standard of Care
17 Not yet recruiting CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas
Condition: Grade II/III Glioma
Interventions: Drug: Temozolomide;   Radiation: Radiotherapy
18 Recruiting Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Conditions: Solid Tumors (Phase 1);   Relapsed/Recurrent GBM (Phase 2)
Interventions: Drug: USL311;   Drug: Lomustine
19 Not yet recruiting NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
Conditions: Acute Myeloid Leukemia;   Leukemia;   Myeloid Leukemia
Interventions: Drug: cyclophosphamide;   Drug: Fludarabine;   Procedure: NK cell infusion;   Drug: IL-2
20 Not yet recruiting A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cel Lymphoma (DLBCL)
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Rituximab (RTX);   Drug: MOR208;   Drug: Bendamustine (BEN)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years